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Abstract The European Paediatric Influenza Analysis
(EPIA) project is a multi-country project that was created
to collect, analyse and present data regarding the paediatric
influenza burden in European countries, with the purpose of
providing the necessary information to make evidence-
based decisions regarding influenza immunisation recom-
mendations for children. The initial approach taken is based
on existing weekly virological and age-specific influenza-
like illness (ILI) data from surveillance networks across
Europe. We use a multiple regression model guided by
longitudinal weekly patterns of influenza virus to attribute
the weekly ILI consultation incidence pattern to each
influenza (sub)type, while controlling for the effect of
respiratory syncytial virus (RSV) epidemics. Modelling the
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DOI 10.1007/s00431-010-1164-0ILI consultation incidence during 2002/2003–2008 revealed
that influenza infections that presented for medical attention
as ILI affected between 0.3% and 9.8% of children aged 0–
4 and 5–14 years in England, Italy, The Netherlands and
Spain in an average season. With the exception of Spain,
these rates were always higher in children aged 0–4 years.
Across the six seasons analysed (five seasons were
analysed from the Italian data), the model attributed 47–
83% of the ILI burden in primary care to influenza virus
infection in the various countries, with the A(H3N2) virus
playing the most important role, followed by influenza
viruses B and A(H1N1). National season averages from the
four countries studied indicated that between 0.4% and
18% of children consulted a physician for ILI, with the
percentage depending on the country and health care
system. Influenza virus infections explained the majority
of paediatric ILI consultations in all countries. The next
step will be to apply the EPIA modelling approach to
severe outcomes indicators (i.e. hospitalisations and mor-
tality data) to generate a complete range of mild and severe
influenza burden estimates needed for decision making
concerning paediatric influenza vaccination.
Keywords Influenza.Children.Paediatric.Burden of
disease.Modelling.Europe
Introduction
Influenza A and B viruses cause winter-seasonal epidemics
of respiratory illness in the northern hemisphere that have
been reported to affect 5–15% of the population each winter
[40], with reports of paediatric attack rates between 20%
and 35% depending on season and methodology. Symp-
toms of the disease vary from mild (e.g. requiring little or
no treatment) to severe (e.g. requiring hospitalisation).
Though death is more common in the elderly and popu-
lations that have a higher risk of developing complications
following an influenza virus infection (e.g. persons with
chronic heart and lung diseases, diabetes, immunodeficien-
cy, pregnancy etc.), severe disease and some deaths occur
each season in healthy young and middle-aged adults and
children.
Recommendations to vaccinate high-risk populations
and persons over 65 years have been implemented in
Europe since the 1980s/1990s (1999/2000 season in the
UK) [7, 24, 33]. With minor exceptions, vaccination rec-
ommendations are broadly similar across Europe, with most
countries recommending the vaccination of persons over
65 years and high-risk groups. In Hungary, Germany and
The Netherlands, the age threshold is 60 years; in Finland
(since 2007), vaccination of children aged 6–35 months
is recommended; in Austria, vaccination is recommen-
ded for persons of all ages [27]. All countries in Europe
aim to meet the WHO Assembly goal of vaccinating 75%
of high-risk groups by 2010. Results of a regional
(European Union and European Economic Area) survey
published in 2008 indicated that influenza vaccination
coverage rates in the elderly (i.e. ≥65 years) varied subs-
tantially from less than 10% in some countries to over
70% in others [27].
Several countries, including Argentina, Canada, Finland,
Mexico, Singapore and the USA, have recently extended
their vaccination recommendations to include younger age
groups [41]. These decisions were based, in part, on evi-
dence demonstrating that influenza has substantial adverse
impacts among school-age children and their contacts (e.g.
significant school absenteeism, antibiotic use, medical care
visits and parental work loss) compared to uninfected or
asymptomatic children [5, 15, 17, 28]. Additionally, studies
have suggested that vaccination of children has the
potential to reduce influenza among their household
contacts and within the community, thereby reducing the
risk of influenza even in high-risk groups (herd immunity)
[18, 32, 39]. The US recommendations have recently
evolved from 6 to 23 months in 2004 to 6–59 months in
2006 to now include all children up to 18 years of age. The
increasing focus on paediatric age groups was in large part
fuelled by the heightened awareness of paediatric influenza
mortality starting with the severe 2003–2004 Fujian A
(H3N2) season [2, 3].
In 2007, a scientific panel on vaccines and immunisa-
tion, in conjunction with the European Centre for Disease
Prevention and Control (ECDC), published a technical
report on routine influenza vaccination in children [36]. The
report emphasised that the first step towards any decision
regarding routine immunisation in children is to determine
specific national profiles of the disease burden. Estimates of
the burden of influenza in children using sentinel practice
data from England and Wales suggested that in a typical
winter epidemic between 1987/1988 and 1996/1997, 1.2%
of children aged 0–4 and 1.1% of children aged 5–14 years
sought medical attention and were diagnosed with ILI; in
addition, many more children were diagnosed with other
respiratory syndromes such as acute bronchitis and otitis
media [14]. The same study using similar data from The
Netherlands estimated that 3.0% of children 0–4 years and
1.9% of children 5–14 years had medically attended ILI in
a season. Paradoxically, the Dutch general practitioners,
who reported a higher seasonal ILI percentage, worked with
a stricter case definition than in the UK.
Because the ECDC report concluded that paediatric
disease burden estimates were scarce in most European
countries and that this would hamper the ability of countries
to make policy decisions about the influenza vaccine, the
European Paediatric Influenza Analysis (EPIA) project was
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influenza burden data in countries across Europe. The
approach taken by EPIA was to base the modelling on the
robust virological and epidemiological surveillance net-
works in European countries to generate country-specific
disease burden estimates for mild illness (ILI), severe
illness (e.g. pneumonia hospitalisations) and mortality.
Here, we present the EPIA project, its methods, planned
studies and results so far.
The EPIA project
Background
Table 1 outlines the different types of data that have been
(or will be in the future) collected by EPIA. The project was
formed around the European Influenza Surveillance
Scheme (EISS) [10], and the first modelling work has
centred on the ILI data and virological data collected by
this network from 1996 up to 2008. Both the ILI and
virological data were collected weekly for the winter
periods (i.e. seasons) from week 40 (October) to week 20
(May) of the following year. Data have been collected
according to a case definition (in most countries), and the
sentinel physicians took nose/throat swabs from a selection
of their patients and sent the specimens to their National
Influenza Centre to validate the clinical reports made by the
sentinel physicians and to determine virus characteristics
(i.e. (sub)type) which might impact the severity of disease
and extent of virus circulation (e.g. Arkema et al. [1]).
While multiple ILI consultations in the context of a single
episode are not reported by physicians, multiple episodes
for the same patient are reported on occasion but would
likely represent a small effect on the incidence estimates
reported in the current study.
The virological data were obtained from weekly sentinel
and non-sentinel reports from National Influenza Centres,
with the sentinel data coming from the sentinel surveillance
systems and the non-sentinel specimens coming from
other sources (e.g. hospital and peripheral diagnostic
laboratories). As most sentinel specimens have been tested
for influenza and RSVs, with the exception of Spain, the
National Influenza Centres provide weekly data on both
viruses. Within three of the four country datasets (England,
The Netherlands and Spain), the majority of the RSV data
were non-sentinel in nature (in The Netherlands and Spain,
these data were obtained from separate surveillance
systems: the Dutch Working Group on Clinical Virology
in The Netherlands and the Microbiological Information
System in Spain), but valid inclusion was assumed based
on published reports of these isolates being derived from
mostly children [14, 16, 38]. Laboratories within the EISS
system regularly participated in quality control assessments
reported elsewhere [25, 26]. RSV is a virus that often
represents a confounding variable in influenza research of
this type as its resulting infection can produce similar
symptoms and the virus often circulates in a seasonal
pattern along with influenza viruses [11]. Whilst the ILI
data are age specific (0–4, 5–14, 15–64 and 65+), the
virological data were only available for all ages; for the
purpose of EPIA modelling, we have assumed that all-age
epidemic patterns for influenza virus and RSV detections
are representative of epidemic patterns (intensity and
duration) in the paediatric age groups, a generally accepted
method within this area of research (e.g. [13, 14, 19, 30]).
To estimate the contribution of moderate and severe
outcomes due to influenza virus and RSV infections, EPIA
is also collecting weekly or monthly hospital (and, in the
case of Denmark, emergency department) discharge data
from each country. To this end, EPIA has developed a list
of influenza-relevant ICD-9 and ICD-10 code ranges and
submitted requests for extraction of data, stratified by up to
24 age groups. These ICD-coded definitions are also being
used to obtain mortality data from each country. The
current study focuses entirely on the modelled burden of
physician-intended ILI in children (in the outpatient
setting). Analyses of inpatient and mortality data will be
published separately.
Participating countries
All European countries are invited to participate in the
EPIA project provided they have several years of virolog-
ical data (weekly counts of subtyped influenza viruses and
RSVs) and data from at least one outcome of interest; for
example, ILI or inpatient data. Currently, the following
seven countries participate in the EPIA project: Denmark,
England, Finland, Italy, The Netherlands, Scotland and
Spain. In this paper, we report results from a subset of
EPIA member countries for which the ILI data and virology
data had been obtained, cleaned, analysed and discussed
with the country collaborators.
Management and underlying sponsorship
The private–public EPIA collaborative project is funded by
MedImmune, the wholly owned biologics business for
AstraZeneca PLC. The project is being implemented by
SDI, a US market insight and analytics firm that consol-
idates electronic healthcare data (e.g. RSV surveillance in
the USA [4]) for clients in the private and public sectors.
The partner, NIVEL, is located in The Netherlands and is a
not-for-profit research foundation. NIVEL is responsible for
coordinating EPIA activities in Europe based on its ex-
perience with the coordination of the EISS from November
1999 to September 2008 [10].
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clearly independent of its underlying sponsor through the
following measures:
1. SDI, NIVEL and MedImmune have signed a Memo-
randum of Understanding which ensures that Med-
Immune is not involved in the study design, analysis,
publication (aside from pre-publication review of the
final manuscript) or management of the EPIA project
(http://www.nivel.eu/epia/).
2. An independent Steering Committee (see below) has
been established to supervise the EPIA project and
ensure, that the Memorandum of Understanding is
followed.
3. Documents detailing the guiding principles enumerated
in Box 1 were agreed upon by EPIA members. These
principles clearly define the operating procedures with
respect to data analyses, authorship, data ownership and
conflict resolution.
The EPIA Steering Committee is comprised of five persons
from various European Union Member States representing
the following fields: influenza researchers, paediatricians,
epidemiologists and virologists. In addition, a liaison from
ECDC participates in Steering Committee and member
meetings.
Box 1 Guiding principles of the European Paediatric
Influenza Analysis project
Guiding principles
● Data ownership/sharing is decided by members or according to rules
of data sources (e.g. private sector data)
● EPIA is open to all countries in Europe
● Models are shared with national collaborators
● Multi-country and national publications are supported
● EPIA is a publication-driven project
● EPIA is a research project, not a surveillance project
● A Memorandum of Understanding between the sponsor and the
project managers ensures the sponsor does not influence data analysis
or interpretation
● The sponsor does not have access to the EPIA data
● The project is guided by an independent Steering Committee
Methods
Description of data and data sources utilised in the current
study
The underlying surveillance effort for each country is
described here; the ILI case definitions are tabulated below
(Table 2).
England The Royal College of General Practitioners
Weekly Returns Service (WRS) includes approximately
500 general practitioners (GPs) covering 1.8% of the entire
population and is representative of age, sex, socioeconomic
status and ethnicity [12]. During winter, network GPs are
asked to collect nasal/nasopharyngeal specimens from a
sample of ILI patients for virological testing. Over each of
the last five winters approximately 1,000 samples have
been submitted for virological determination. The WRS
collects incident case data from age- and gender-specific
defined populations for all diagnoses including ILI. Partic-
ipating doctors are given guidance on diagnosing specific
diseases but are asked to record the diagnosis using the
diagnostic term most appropriate to the clinical presentation.
Italy The Italian epidemiological surveillance network
consists of 762 sentinel GPs and 213 paediatricians
reporting ILI cases on a weekly basis during the winter
Table 1 Data types collected by EPIA for disease and pharmacoeconomic burden estimation
Weekly outpatient visits from sentinel physicians (ILI data)
Weekly virological data from sentinel and non-sentinel sources (influenza and RSV data)
Weekly or monthly hospitalisation data: pneumonia, sepsis and more; outcomes may include numbers of visits, hospital days and the cost of the
event
Weekly or monthly emergency department data
Weekly or monthly antibiotic utilisation data
Weekly or monthly mortality data: influenza and pneumonia, sepsis and more
Age strata <3, 3–5, 6–12 months; 1, 2, 3, 4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–
74, 75–79, 80–84, Q85 years old
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for age, geographic distribution and urbanisation level.
Each participating doctor is given instructions on which day
to take the swabs; they collect samples from the first ILI
cases observed during the pre-specified days. The average
number of samples collected since 2000 was 2,500 per
season.
The Netherlands The Dutch network consists of approxi-
mately 65 GPs (across 45 practices) covering about 1% of
the total population, which is representative of age, sex,
geographic distribution and urbanisation level. During
winter, sentinel GPs are asked to collect nasal/nasopharyn-
geal specimens from randomly selected patients with ILI
for virological testing. These physicians are asked to collect
specimens from at least two patients per week preferentially
including one younger than 10 years of age, irrespective of
symptom severity. Network-wide averages of approximate-
ly 20 specimens are collected every week during the
season.
Spain The Spanish Influenza Sentinel Surveillance System
consists of about 497 GPs and 171 paediatricians covering
approximately 2% of the national population and is repre-
sentative of age, sex and urbanisation level. During winter,
sentinel GPs and paediatricians collected nasal/nasopharyn-
geal specimens from a subset of ILI patients, yielding about
35 samples per week for virological testing [23].
Modelling
A direct assessment of the influenza disease burden is not
possible because influenza virus infection is rarely confirmed
by laboratory testing and because a triggering influenza virus
infection may have resolved by the time a patient presents
with secondary complications (e.g. bacterial pneumonia).
Instead, inferential statistical methods (e.g. regression mod-
elling) and outcome data (e.g. physician consultations
diagnosed as ILI) are commonly used to estimate the
seasonal disease burden specific to influenza virus infection
(i.e. to understand how ILI rates vary with any one of the
independent viral variables).
Modelling the paediatric burden of influenza is further
complicated by the concurrent impact of other important
respiratory pathogens, especially RSV, which often co-
circulates with influenza viruses during winter months.
Importantly, the model is capable of estimating the
contribution of influenza virus infection to physicians’ ILI
consultation incidence while controlling for the effects of
RSV on the dependent variable (i.e. weekly ILI rate). The
model was created to estimate the seasonal influenza
burden in paediatric age groups; in this paper, data for
children 0–4 and 5–14 years of age are presented. However,
the model may also be applied to adult age groups and
could also be used to generate burden estimates for the
ongoing 2009 A(H1N1) pandemic in near real time for
medically attended illness (e.g. ILI, pneumonia and/or
influenza).
Four participating countries with readily available ILI
and linked virologic data needed for the modelling were
used to develop the multiple regression model employed in
the current study. All available seasons where virological
data were stable (i.e. seasons with simultaneous surveil-
lance of both influenza virus and RSV) were analysed.
Additionally, two sensitivity analyses were conducted. The
first analysis was undertaken to investigate the consequence
of overlapping RSV and influenza epidemics by restricting
the Dutch data to three seasons (2002–2005) where
Table 2 Case definitions of influenza-like-illness employed by EPIA countries included in this paper
Surveillance network Case definition
England No absolute case definition but physicians are advised to include illness with a sudden onset, fever or
feverishness, one or more respiratory and one or more systemic symptom (e.g. headache, muscle pains)
Italy Sudden onset of symptoms, with temperature >38°C, plus at least one of the following systemic symptoms:
headache, malaise, chills, sweats, fatigue; plus at least one respiratory symptom (cough, sore throat, or
nasal obstruction)
Note: In very young children, physicians are advised to consider that (1) they are not able to describe
symptoms and often have nonspecific signs such as: irritability, anorexia, crying; (2) vomiting and
diarrhoea are common symptoms in neonates, while fever is uncommon; (3) conjunctivitis is often
associated with influenza in pre-school children; and (4) in children between 1 and 5 years of age,
the most important influenza symptoms are fever with laryngitis and/or bronchitis
The Netherlands An acute onset (at most a prodromal stage of 3 to 4 days), accompanied by a rise in rectal temperature of
>38°C, and at least 1 of the following symptoms: cough, coryza, sore throat, frontal headache, retrosternal
pain, myalgia
Spain At least 4 of the following characteristics in the context of an influenza epidemic (6 criteria are needed in the
absence of an influenza epidemic): acute onset (within 12 hours), cough, fever, chills, prostration and
weakness, myalgia or general pain, rhinitis, pharyngitis, contact with a case
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neously. The second sensitivity analysis was conducted to
assess the effects of incomplete RSV virology data on
model estimates of ILI attributed to RSV by restricting the
Italian data to THE two seasons (2005–2007) which
contained the majority of RSV-positive test reports. In the
next phase of the project, EPIA collaborators will apply the
model to data from moderate and severe outcomes (e.g.
hospitalisation and mortality), while modifying the regres-
sion equation to account for secular and seasonal patterns in
the data. The influenza burden estimates derived from the
model will then be applied in the pharmacoeconomic
analysis, enabling elucidation of the financial consequences
of the disease.
A multiple linear regression model approach was
generated in both SAS (the GENMOD procedure) and
Stata (the GLM command) [34, 35] formats and shared
with EPIA member countries along with the offer of
statistical and publishing support. The goal is for the indi-
vidual countries to carry out subsequent national analyses
(using their country-specific data) and publish the results.
The modelling approach described below was chosen to
capitalise on the existing viral surveillance data and to
allow for investigation of individual virus (sub)types. Its
basic form is:
ILI ratet ¼ b0 þ b1   RSVt þ b2   InfA H3N2 ðÞ t þ b3
  InfA H1N1 ðÞ t þ b4   InfBt
where the ILI rate is the population incidence of ILI and the
index t represents the running week during the study
period. The term β0 represents a constant (assumed stable
across the time period of study) and β1–β4 the regression
coefficients for each of the pathogens RSV, influenza A
(H3N2), A(H1N1) and influenza B.
The initial model was applied to each country and age
strata utilising weekly counts (versus percent of positives,
which typically plateaus for many weeks during an
epidemic and therefore does not always reflect virus peaks)
of positive tests for each of the virus types and subtypes
(influenza B, A(H3N2), A(H1N1) and RSV). When one of
these terms was not statistically significant (p value >0.2) in
the model or if the coefficient was negative (suggesting the
pathogen prevented ILI and thus not biologically plausible),
the term was omitted from the final model.
Model fit and attribution of ILI to each pathogen
The model-predicted and observed weekly ILI rates were
compared, and for most age groups and countries, the
visual fit of the model, in terms of tracking peaks, was
satisfactory (see Fig. 1). Additional regression analyses
revealed that the modelled ILI values predicted the
observed ILI values reasonably well (average R
2 value
across all countries and age groups was 0.65; average
standard deviation was 0.07). The weekly attribution of ILI
rate to each pathogen was generated by multiplying each
regression coefficient by its corresponding weekly virus
count. We interpret the constant β0 to indicate the var-
iability caused by respiratory pathogens other than influen-
za and RSV combined with measurement error.
Finally, we computed the seasonal attribution by summing
the attribution components of eachpathogen from week 40 to
week 20 of the following year. The percentage of ILI
attributed to each virus was calculated using the predicted
sum of ILI across the winter weeks as the denominator. The
goal of the modelling was to determine the burden of influen-
za across seasons, age groups and countries; the RSV term in
the model controls for the simultaneous contribution of RSV
to the ILI signal.
Results
The results presented in this section are reported as averages
across seasons, within each country and age group. Results
from individual seasons are reported in Table 3.
England An average of 581 per 100,000 children aged 0–4
visited a physician for ILI each season during 2002–2008.
The model attributed an average of 56% of these
consultations (354 per 100,000) to influenza viruses and
16% (83 per 100,000) to RSV. The remaining 28% of ILI
rate was unaccounted for by the model (see Fig. 1 for
graphical depiction of the results from this age group). For
children aged 5–14 years, 409 per 100,000 consulted a
physician for ILI during an average season. The model
attributed 77% of these ILI visits (i.e. 315 per 100,000) to
influenza viruses and 11% (43 per 100,000) to RSV, while
an average 13% was unattributed by the model.
Italy The Italian study period was, at first, limited to 2004–
2007 to ensure adequate RSV surveillance data. When the
RSV terms did not contribute significantly to the model
(p>0.2 for both paediatric age groups), the analyses were
expanded to include 2003–2008, for which subtyped
influenza surveillance data were available. Results of the
Italian sensitivity analysis also yielded non-significant RSV
terms.
Across these five seasons, an average of 17,748 per
100,000 children aged 0–4 (18%) visited their physician for
ILI; the model attributed 52% of these visits to influenza
virus types A and B combined, corresponding to 9.8% of
all children aged 0–4 years. The remaining 48% of ILI was
unattributed by the model (see Fig. 1). Within the 5–14-
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physician for ILI. The model attributed 63% of these visits
(i.e. 8,915 per 100,000 or 8.9% of the population) to in-
fluenza virus types A and B combined, while the remaining
ILI variance was unexplained by the model.
The Netherlands During the six seasons 2002–2008, an
average of 1,973 per 100,000 children aged 0–4 years
consulted their physician for an ILI. The model attributed
47% (i.e. 925 per 100,000) of ILI to influenza virus and
20% (i.e. 382 per 100,000) to RSV, while 33% was
unattributed (see Fig. 1). A winter average of 970 per
100,000 Dutch children aged 5–14 years visited their
physician for ILI. The model attributed 62% (i.e. 632 per
100,000) of the ILI consultations to influenza virus and
13% (i.e. 121 per 100,000) to RSV. An average 25% ILI
variance was unattributed.
Results of the Dutch sensitivity analysis revealed that of
the 1,358 per 100,000 ILI visits within the 0–4-year-old
group, the model attributed 70% (i.e. 964 per 100,000) visits
to influenza, 13% (i.e. 170 per 100,000) to RSVand 17% to
other factors. Within the 5–14-year-old group, there was an
average 852 ILI visits per 100,000 children. Of these visits,
the model attributed 78% (i.e. 676 per 100,000) to influenza.
RSV did not contribute significantly to the model (p=0.4),
and 22% of ILI was unattributed.
Spain During 2002–2008, there was a seasonal average of
2,686 per 100,000 children aged 0–4 years who sought
medical attention for ILI. The model attributed 80% of
these cases (2,156 per 100,000) to influenza virus types A
and B. RSV was not a significant factor in the model (p=
0.37) and 20% of ILI was unattributed (see Fig. 1). For the
5–14-year-olds, 3,558 per 100,000 children visited their
physician with ILI. The model attributed 83% (i.e. 2,955
per 100,000) of the ILI cases to influenza. RSV was not a
significant term in the model (p=0.23), and 17% of the ILI
variance was unattributed.
Fig. 1 Observed and predicted physician consultations for ILI by country. In countries where RSV contributed significantly to the observed ILI
rate (i.e. England and The Netherlands; upper portion of figure), influenza viruses were grouped together
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This paper outlines the design of the EPIA project, the
modelling approach, and provides initial modelling results of
the burden of medically attended influenza illness in four
member countries and for two paediatric age groups. Across
the four countries and two age groups investigated in this
study, the total ILI burden varied widely between countries,
with seasonal averages between 0.4% and 18% (mean=5.2%;
median=2.4%) of the populations studied. Influenza epidem-
ics were responsible for most of these ILI events, with
seasonal averages of 0.3–9.8% (mean=1.6%; median 3.3%)
observed across countries and age groups. Calculated ILI
consultation incidences for the UK and The Netherlands were
slightly lower than those reported previously over the period
1986–1997 [14], which is in line with other reports of
decreasing incidence of ILI in recent years [9]. With the
exception of Spain, data from all countries revealed a higher
incidence of influenza-attributed physician consultations in
children aged 0–4 years. These findings are consistent with
prior reports of younger children (e.g. infants and toddlers)
bearing the highest influenza burden [9].
As seen in Table 3, the results presented from the
current study reflect considerable between-country variabil-
Table 3 Seasonal incidence rates of observed ILI consultations and rates attributed to influenza and RSV by country and age group (per 100,000
children)
Observed ILI Influenza A(H1N1) Influenza A(H3N2) Influenza B RSV
0–4 years 5–14 years 0–4 years 5–14 years 0–4 years 5–14 years 0–4 years 5–14 years 0–4 years 5–14 years
England
a
2002–2003 681 480 n.c. n.c. 94 51 67 161 93 48
2003–2004 1,140 485 n.c. n.c. 700 381 7 17 79 41
2004–2005 711 414 n.c. n.c. 316 172 35 84 81 42
2005–2006 490 593 n.c. n.c. 141 77 140 337 86 44
2006–2007 306 298 n.c. n.c. 465 253 7 16 60 31
2007–2008 160 186 n.c. n.c. 17 9 137 330 97 50
Italy
b
2003–2004 14,522 10,338 251 153 4,280 4,252 1,018 1,057 n.s. n.s.
2004–2005 23,242 20,608 2,303 1,400 6,943 6,898 10,302 10,702 n.s. n.s.
2005–2006 11,347 7,927 3,513 2,135 551 547 2,810 2,919 n.s. n.s.
2006–2007 19,066 12,780 5,117 3,110 4,664 4,634 1,466 1,523 n.s. n.s.
2007–2008 20,562 15,546 1,554 945 156 155 3,991 4,145 n.s. n.s.
The Netherlands
c
2002–2003 855 676 28 n.s. 286 197 246 190 251 79
2003–2004 1,510 697 0 n.s. 734 505 15 12 332 105
2004–2005 1,710 1,183 83 n.s. 641 442 558 431 363 115
2005–2006 2,472 1,374 7 n.s. 313 215 714 551 474 150
2006–2007 2,148 787 50 n.s. 547 377 25 19 415 131
2007–2008 3,142 1,104 192 n.s. 51 35 1,061 819 457 144
Spain
d
2002–2003 1,842 4,075 405 293 37 47 633 1,398 n.s. n.s.
2003–2004 2,919 3,130 0 0 1,544 1,950 3 7 n.s. n.s.
2004–2005 3,121 4,176 20 15 1,968 2,486 307 678 n.s. n.s.
2005–2006 2,396 3,278 785 568 173 219 595 1,314 n.s. n.s.
2006–2007 2,552 2,996 112 81 2,915 3,682 242 534 n.s. n.s.
2007–2008 3,283 3,694 1,719 1,243 52 65 1,425 3,148 n.s. n.s.
N.B., each winter season was defined as week40 (October) to week20 (May of the following year)
n.c. negative regression coefficient, n.s. non-significant
aPopulation of English children 0–4 years, 3.0 M; 5–14 years, 6.0 M [29]
bPopulation of Italian children 0–4 years, 2.7 M; 5–14 years, 5.5 M [11]
cPopulation of Dutch children 0–4 years, 1.0 M; 5–14 years, 2.0 M [11]
dPopulation of Spanish children 0–4 years, 2.2 M; 5–14 years, 4.1 M [11]
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infections, with England having the smallest burden and
Italy the highest. These international differences may be
influenced by a number of factors. Case definitions, for
example, vary between the countries studied (as a function
of the fact that many national surveillance networks predate
the establishment of the international EISS network). The
number of symptoms required to diagnose a patient with
ILI as well as specific symptoms themselves are not
homogeneous across the countries analysed (i.e. fever is
not necessary to diagnose ILI in all countries possibly
allowing for a diagnosis in one country that would not
otherwise be made in another). Many ILI symptoms are
also subjective (e.g. weakness, myalgia, irritability) and
diagnosed by self-report or parental reports, which may be
sensitive to sociocultural differences between countries
(e.g. the outlook of parents on what paediatric symptoms
merit a visit to the doctor). Cultural and/or training
differences may also play a role on the part of the diag-
nostician as well as adherence to case definitions. Health
systems may also impact health-seeking behaviour through
their funding structures, shortages of primary care physi-
cians or other factors that could discourage patients from
seeking care such as excessive waiting times, limited
physician office hours or appointments.
Provision of primary care in paediatric populations may
play a role in health-seeking behaviour as well. Paediatric
primary care in Europe can be categorised into three
distinct groups: (1) paediatrician-led, (2) GP-led and (3) a
combination of the two [22]. Two of the EPIA countries
discussed (England and The Netherlands) represent the GP-
led primary care system, where GPs act as ‘gatekeepers’ to
more specialised care, while Spain has a paediatrician-led
system and Italy a combined system (young children are
generally cared for by paediatricians while school-age
children have the option to see either a paediatrician or a
GP [6]). Thus, our reported between-country differences are
in agreement with more conservative health-seeking behav-
iour in GP-led primary care systems and far higher numbers
of visits in the paediatrician-led systems. It is also important
to note two specific points regarding the situation in Italy,
where the highest ILI consultation rates were observed.
There are more paediatricians in Italy than any other
country in Europe, perhaps creating an environment where
consulting a physician is easier for parents in this country
compared to others. Additionally, there is a separate, more
inclusive, case definition used to diagnose ILI in Italian
children. Paediatric-specific ILI case definitions are not
employed in the other countries studied.
The finding that an average (across countries and age
groups)of27% (range13–48%)ofthe observedILIincidence
in children was not attributed to influenza or RSV by the
model is in agreement with laboratory-based studies where,
depending on the time point during winter, a varying
proportion of ILI cases are determined to be due to respiratory
pathogens other than influenza and RSV [37]. Thus,
pathogens including adenoviruses, metapneumovirus, para-
influenza viruses and Streptococcus pneumoniae may ex-
plain some of the residual (unexplained) ILI consultations.
However, the importance of influenza driving the ILI signal
was evident as the ILI peak always coincided with the peak
incidence in influenza virus data. Ideally, it would be useful
to expand the model to include additional pathogens.
The low average seasonal attribution to influenza A
(H1N1) viruses in England and The Netherlands (≤0.1%
compared to the range of 0.4% (5–14 years old in Spain)
and 2.6% (0–4 years old in Italy)) may reflect its low
circulation during the study period 2002–2008 in those
countries. Interestingly, our model attributed a relatively
small proportion of ILI visits to RSV—a proportion that
dropped further in the Dutch data sensitivity analysis when
limiting the model period to seasons with discrete (rather
than overlapping) RSV and influenza epidemics. Thus, our
modelling approach likely tended to overestimate the RSV
contribution to outpatient ILI visits.
A direct comparison between previous reports and the
current study is not straightforward as the methods
employed, range of study years and the outcomes under
study are not identical. For example, the study of Fleming
et al. [13] was based solely on paediatric RSVand influenza
during 1994–2000 and studied a more inclusive outcome,
acute respiratory infections. The study of Pitman et al. [30]
utilised (among other datasets) national laboratory data for
several viruses from 1990 to 2004 and numbers of
outpatient consultations for all acute respiratory infections
recorded in the General Practice Research Database during
the winter of 2002 to 2003. The study of Jansen et al. [20]
utilised data from Dutch outpatients using a broader range
of diagnoses that would not be captured in the ILI case
definition, and utilised GP data from a single regional
network rather than a national sentinel network. These three
studies [13, 20, 30] all found larger incidence rates of RSV,
which emphasises that there is a need for data encompass-
ing all acute respiratory infections (in order to capture more
of the RSV burden), data which is not available in all but
one of the EPIA countries (England) and as such could not
be presented in this multi-country paper.
One additional limitation of EPIA between-country
comparisons is that no standardised protocol was used in
the national influenza surveillance systems in Europe;
despite EISS collaborations since the 1990s [1], the
surveillance systems in each country have a different
history, meaning that each country uses a different case
definition and different types of reporting physicians (see
Table 1), providing multiple opportunities for potential
bias in estimated incidence rates. Efforts to harmonise the
Eur J Pediatr (2010) 169:997–1008 1005surveillance systems were initiated by the EISS project (e.g.
age groups and virological swabbing forms [1]), but
differences remain and these almost certainly affect the
incidence estimates. Because of this, we have chosen to
present results by country and not for all countries grouped
together.
With the modelling approach firmly established, the next
steps for EPIA will be to extend the analysis to consider
more severe outcomes of paediatric influenza, such as
hospitalisations and deaths. Also, EPIA plans a number of
special subset studies to investigate the consequence of
different ILI case definitions in different countries, and the
introduction of more viral respiratory pathogens into the
model. Furthermore, an expanded age group analysis will
be done to study the influenza versus RSV burden in
infants. Finally, the emergence of the pandemic A(H1N1)
swine-origin influenza virus in the spring of 2009 may
inspire countries to use the EPIA model to estimate, near
real time, the burden of this emerging virus in the sub-
sequent winters when co-circulation of seasonal influenza
viruses and RSV may occur.
The models developed and applied in the EPIA
project will facilitate research to derive country-specific
results indicating the national burden of paediatric
influenza disease in each of the member countries. The
overall objective will be to publish this burden of
disease data (including pharmacoeconomic analyses) to
inform paediatric vaccination recommendations. These
analyses concern a very large population in Europe, with
more than 52 million inhabitants in the European Union
being children aged 0–14 [8]. Our results so far
demonstrate that there was a substantial outpatient febrile
respiratory disease burden in some countries of the
European Union in an average season between the years
of 2002 (2003 in Italy) and 2008: In Italy, 9% to 10% of
a l lc h i l d r e na g e d0 –14 visited their physician with
influenza; in Spain, 2–3%; and in England and The
Netherlands, <1%.
It is important to bear in mind that our results represent
an underestimate of the influenza burden for several
reasons: (1) the outcome measured excludes cases of
influenza that were treated in other settings (i.e. hospitals
and emergency departments) or those that were not
professionally attended to, and (2) not all influenza
infections are diagnosed as ILI.
As national profiles of paediatric influenza disease
burden are determined, new issues and knowledge gaps
must be considered. The pharmacoeconomic impact (e.g.
cost–benefit analyses) of implementing a new recommen-
dation should be investigated in addition to programmatic
issues including feasibility and sustainability (from both
financial and logistical perspectives). Finally, although
safety, tolerability and efficacy of currently licensed in-
fluenza vaccines have been established [21], post-licensure
surveillance is crucial to monitor serious adverse events,
coverage, effectiveness and the long-term effects on the
population [8, 31]. EPIA aims to provide some of the
elements that will help support evidence-based decisions
regarding influenza vaccination recommendations for chil-
dren in Europe.
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